# Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

> **NCT00906516** · PHASE2 · UNKNOWN · sponsor: **Bradmer Pharmaceuticals Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Brain Tumors

## Interventions

- **DRUG:** Neuradiab in combination with Bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT00906516
- **Lead sponsor:** Bradmer Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-05
- **Primary completion:** 2010-09
- **Final completion:** 2010-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2009-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00906516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00906516, "Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00906516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*